Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
Emerging nanomedicine approaches to targeting HIV-1 and antiretroviral therapy
Ist Teil von
Future virology, 2016-02, Vol.11 (2), p.101-104
Ort / Verlag
England: Future Medicine Ltd
Erscheinungsjahr
2016
Link zum Volltext
Quelle
Taylor & Francis
Beschreibungen/Notizen
[...]only half of the 14 million people eligible for combination antiretroviral therapy (cART) are currently receiving it (4). Development of the nanomedicine's drug delivery system in conjunction with the therapeutic can result in optimization for efficacy and safety rather than focusing on solubility and permeability. [...]the nanomedicine, which will dictate the cellular exposure and pharmacokinetics of the therapeutic, can be tailored to provide sustained release of drug or rapidly degraded in the presence of an enzyme at site of action. [...]maintaining current plasma drug concentrations, which have acceptable systemic side effects, will increase intracellular drug concentrations with the aim of shortening the duration of treatment. Clearly increasing intracellular drug concentrations while minimizing systemic exposure and toxicity in healthy tissue will improve drug therapy outcomes, and avoid unwanted side effects. [...]the development of nanomedicines with exceptionally long half-lives containing small-molecule therapeutics that were previously thought to have clinically limiting physicochemical and/or pharmacokinetic properties is now viable.